Amgen Gets The First BiTE
Executive Summary
On December 3, FDA approved Amgen Inc.’s bispecific T-cell engager (BiTE) Blincyto for forms of relapsed or refractory acute lymphocytic leukemia, less than two months after accepting the company’s Biologics License Application and more than five months ahead of its user-fee goal of May 19, 2015.